US Stock MarketDetailed Quotes

AKRO Akero Therapeutics

Watchlist
  • 29.340
  • +0.940+3.31%
Close Dec 20 16:00 ET
  • 29.340
  • 0.0000.00%
Post 16:11 ET
2.05BMarket Cap-7.76P/E (TTM)

About Akero Therapeutics Company

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Company Profile

SymbolAKRO
Company NameAkero Therapeutics
Listing DateJun 20, 2019
Issue Price16.00
Founded2017
CEODr. Andrew Cheng, M.D.,PhD
MarketNASDAQ
Employees56
Fiscal Year Ends12-31
Address601 Gateway Boulevard,Suite 350
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080-7006
Phone1-650-487-6488

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Andrew Cheng, M.D.,PhD
  • President, Chief Executive Officer and Director
  • 8.83M
  • Dr. Jonathan Young, J.D.
  • Executive Vice President, Chief Operating Officer and Secretary
  • 3.44M
  • William R. White, J.D.
  • Principal Accounting Officer, Executive Vice President, Treasurer, Chief Financial Officer and Head, Corporate Development
  • 4.29M
  • Catriona Yale
  • Chief Development Officer
  • 3.45M
  • Dr. Timothy Rolph, D.Phil.
  • Chief Scientific Officer
  • 3.49M
  • Patrick Lamy
  • Senior Vice President, Commercial Strategy
  • --
  • Mark T. Iwicki
  • Chairman of the Board
  • 606.06K
  • Dr. Graham Waley, M.D.,PhD
  • Independent Director
  • 578.56K
  • Dr. Seth L. Harrison, M.D.
  • Independent Director
  • 568.56K
  • Dr. Judy Chou, PhD
  • Independent Director
  • 571.06K
  • Jane Pritchett Henderson
  • Independent Director
  • 586.06K
  • Tomas J. Heyman
  • Independent Director
  • 581.06K
  • Dr. Yuan Xu, PhD
  • Independent Director
  • 573.56K
Heat List
US
Overall
Symbol
Price
% Chg

No Data